RECORD // Company

Supernus, Inc.

Formerly: Indivior Pharmaceuticals, Inc.; INDIVIOR PLC

Built 2026-11-21T21:59:11Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Records under a former name (4)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (9)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Indivior Inc. · Corp enforcement · name equals 'Indivior' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare
  • Indivior Inc. · Corp enforcement · name equals 'Indivior' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare
  • INDIVIOR INC. · Ct business · name equals 'Indivior' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare
  • Indivior Inc. · Ctgov · name equals 'Indivior' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare
  • INDIVIOR INC. · East licences · name equals 'Indivior' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare
  • INDIVIOR, INC · East licences · name equals 'Indivior' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare
  • INDIVIOR INC · Epa echo · name equals 'Indivior' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare
  • INDIVIOR, INC. · Epa echo · name equals 'Indivior' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare
  • INDIVIOR INC. · Ny corps · name equals 'Indivior' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare

10 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-10-29 · accession 0001628280-26-068013

ItemValuePeriodFormFiledAccessionReport
Revenue$356,000,0003 months ended 2026-09-3010-Q2026-10-290001628280-26-0680132026-11-21 21:59 UTCReport an error
Net income (loss)$137,000,0003 months ended 2026-09-3010-Q2026-10-290001628280-26-0680132026-11-21 21:59 UTCReport an error
Interest expense$2,000,0003 months ended 2026-09-3010-Q2026-10-290001628280-26-0680132026-11-21 21:59 UTCReport an error
Cash and cash equivalents$305,000,000at 2026-09-3010-Q2026-10-290001628280-26-0680132026-11-21 21:59 UTCReport an error
Debt due in the next 12 months (from an earlier report)$59,000,000at 2025-12-3110-K2026-02-260001628280-26-0122372026-11-21 21:59 UTCReport an error
Debt due in year 2 (from an earlier report)$55,000,000at 2025-12-3110-K2026-02-260001628280-26-0122372026-11-21 21:59 UTCReport an error
Debt due in year 3 (from an earlier report)$52,000,000at 2025-12-3110-K2026-02-260001628280-26-0122372026-11-21 21:59 UTCReport an error
Debt due in year 4 (from an earlier report)$50,000,000at 2025-12-3110-K2026-02-260001628280-26-0122372026-11-21 21:59 UTCReport an error
Debt due in year 5 (from an earlier report)$243,000,000at 2025-12-3110-K2026-02-260001628280-26-0122372026-11-21 21:59 UTCReport an error
Debt due after year 5 (from an earlier report)$0at 2025-12-3110-K2026-02-260001628280-26-0122372026-11-21 21:59 UTCReport an error

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001625297
Ticker
SUPN
EIN
412520873
CUSIP
45579U109
Record ID
sx:sec:0001625297

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

34 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-04SEC EDGAR company profile2026-11-21 21:59 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-04SEC EDGAR company profile2026-11-21 21:59 UTCReport an error
State of incorporationDE2026-11-04SEC EDGAR company profile2026-11-21 21:59 UTCReport an error
Fiscal year end (MMDD)12312026-11-04SEC EDGAR company profile2026-11-21 21:59 UTCReport an error
Business address9715 KEY WEST AVENUE, ROCKVILLE, MD, 208502026-11-04SEC EDGAR company profile2026-11-21 21:59 UTCReport an error
ExchangesNasdaq, Nasdaq2026-11-04SEC EDGAR company profile2026-11-21 21:59 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$1,239,000,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 21:59 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$210,000,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 21:59 UTCReport an error
Total assets (at 2025-12-31)$1,201,000,0002025-12-3110-K, XBRL Assets2026-11-21 21:59 UTCReport an error
Stockholders' equity (at 2025-12-31)$-98,000,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 21:59 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$195,000,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 21:59 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-27,000,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 21:59 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$66,000,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 21:59 UTCReport an error
Long-term debt (at 2025-12-31)$290,000,0002025-12-3110-K, XBRL LongTermDebtNoncurrent2026-11-21 21:59 UTCReport an error
Operating lease liabilities (at 2025-12-31)$32,000,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 21:59 UTCReport an error
Unrecorded purchase obligations (at 2025-12-31)$52,000,0002025-12-3110-K, XBRL UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount2026-11-21 21:59 UTCReport an error
8-K Item 8.01, Other (filed 2026-11-03)Pursuant to the terms of the Indenture, dated March 17, 2026, by and between Supernus, Inc. (f/k/a Indivior Pharmaceuticals, Inc.; the “Company” or the “Registrant”) and U.S. Bank Trust Company, National Association (the “Indenture”), governing the Company's 0.625% Convertible Senior Notes due 2031 (the “Notes”), as a result of the Special Dividend that was declared by the Company’s board on September 16, 2026, the conversion rate per $1,000 principal amount of Notes has been increased from 24.0033 shares of the Company’s common stock to 30.9355 shares of the Company’s common stock, which reflects a conversion price of approximately $32.33 per share. The conversion rate is subject to…2026-11-03SEC EDGAR 8-K 0001625297-26-000030 (text as filed, excerpt)2026-11-21 21:59 UTCReport an error
8-K Item 1.01 (filed 2026-11-02)Entry into a Material Definitive Agreement. Credit Agreement On November 2, 2026 (the “Closing Date”), the Combined Company and certain of its subsidiaries (collectively, the “Loan Parties”) entered into a Credit Agreement (the “Credit Agreement”) by and among the Combined Company, as the borrower, the other Loan Parties, as guarantors, the financial institutions from time to time party thereto as lenders, and Citibank, N.A. (“Citi”), as agent for the lenders and for itself as lender, providing for a senior secured term loan facility (the “Credit Facility”) in an aggregate principal amount of $650,000,000, all of which was borrowed on the Closing Date. Capitalized terms used in this Current…2026-11-02SEC EDGAR 8-K 0001104659-26-121013 (text as filed, excerpt)2026-11-21 21:59 UTCReport an error
8-K Item 2.01 (filed 2026-11-02)Completion of Acquisition or Disposition of Assets. The disclosure in the Introductory Note of this Current Report on Form 8-K is incorporated herein by reference. Subject to the terms and conditions of the Merger Agreement, at the Effective Time, and as a result of the Merger, each share of common stock of Supernus, par value $0.001 per share, issued and outstanding immediately prior to the Effective Time (other than Excluded Shares, as defined in the Merger Agreement) was converted into the right to receive 1.5401 shares of Indivior common stock, par value $0.001 per share (such ratio, the “Exchange Ratio” and such shares, following the name change described in Item 5.03 below, “Indivior…2026-11-02SEC EDGAR 8-K 0001104659-26-121013 (text as filed, excerpt)2026-11-21 21:59 UTCReport an error
8-K Item 2.03 (filed 2026-11-02)Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.2026-11-02SEC EDGAR 8-K 0001104659-26-121013 (text as filed, excerpt)2026-11-21 21:59 UTCReport an error
8-K Item 5.02 (filed 2026-11-02)Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Officers Consistent with the terms of the Merger Agreement, effective as of the Effective Time, Joseph Ciaffoni ceased to serve as Chief Executive Officer of Indivior, Ryan Preblick ceased to serve as Chief Financial Officer of Indivior, Patrick Barry ceased to serve as Chief Commercial Officer of Indivior and Jeffrey Burris ceased to serve as Chief Legal Officer of Indivior. Separation Agreement with Joseph Ciaffoni Indivior entered into a separation agreement and release of claims with Joseph Ciaffoni on November 2, 2026 (the…2026-11-02SEC EDGAR 8-K 0001104659-26-121013 (text as filed, excerpt)2026-11-21 21:59 UTCReport an error
8-K Item 5.03 (filed 2026-11-02)Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. As contemplated by the Merger Agreement, effective as of the Effective Time, Indivior amended its certificate of incorporation to change its name from “Indivior Pharmaceuticals, Inc.” to “Supernus, Inc.” A copy of the certificate of amendment is attached hereto as Exhibit 3.1 and is incorporated herein by reference. In connection with the Merger, the Combined Company’s shares of common stock will begin trading on the Nasdaq Stock Market LLC under the ticker symbol “SUPN,” in place of its prior ticker symbol “INDV” on or about November 3, 2026.2026-11-02SEC EDGAR 8-K 0001104659-26-121013 (text as filed, excerpt)2026-11-21 21:59 UTCReport an error
8-K Item 7.01 (filed 2026-11-02)Regulation FD Disclosure. On November 2, 2026, the Combined Company issued a press release announcing the completion of the Merger. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. The information under Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly…2026-11-02SEC EDGAR 8-K 0001104659-26-121013 (text as filed, excerpt)2026-11-21 21:59 UTCReport an error
8-K Item 5.07 (filed 2026-10-15)Submission of Matters to a Vote of Security Holders. On October 15, 2026, Indivior Pharmaceuticals, Inc. (“Indivior”) held a special meeting of its stockholders (the “Indivior Special Meeting”). At the close of business on September 4, 2026, the record date for the Indivior Special Meeting, there were 118,031,934 shares of Indivior common stock (“Indivior Shares”) outstanding and entitled to vote at the Indivior Special Meeting, of which 91,206,182 Indivior Shares were present in person or represented by proxy at the Indivior Special Meeting, representing 77.27% of Indivior Shares outstanding and entitled to vote, which constituted a quorum to conduct business at the Indivior Special…2026-10-15SEC EDGAR 8-K 0001104659-26-116253 (text as filed, excerpt)2026-11-21 21:59 UTCReport an error
Largest institutional holder #1 (13F as filed): BlackRock, Inc.$767,647,9952026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 21:59 UTCReport an error
Largest institutional holder #2 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$310,690,9362026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 21:59 UTCReport an error
Largest institutional holder #3 (13F as filed): OAKTREE CAPITAL MANAGEMENT LP$251,399,5082026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 21:59 UTCReport an error
Largest institutional holder #4 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$225,479,7912026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 21:59 UTCReport an error
Largest institutional holder #5 (13F as filed): STATE STREET CORP$204,824,6732026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 21:59 UTCReport an error
Largest institutional holder #6 (13F as filed): FULLER & THALER ASSET MANAGEMENT, INC.$189,386,9242026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 21:59 UTCReport an error
Largest institutional holder #7 (13F as filed): Two Seas Capital LP$142,763,5982026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 21:59 UTCReport an error
Largest institutional holder #8 (13F as filed): FRANKLIN RESOURCES INC$136,070,1672026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 21:59 UTCReport an error
Largest institutional holder #9 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$129,675,3462026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 21:59 UTCReport an error
Largest institutional holder #10 (13F as filed): Assenagon Asset Management S.A.$126,448,5522026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 21:59 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.